Ketorolac

CHEMBL469 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
255.3 g/mol
LogP
1.9
Phase
4

A potent NSAID used for short-term management of moderate to severe pain, including postoperative pain and pain associated with certain cancers. It is available in oral, injectable, and nasal spray forms and works by blocking prostaglandin synthesis.

Masse moléculaire

255,2700 g/mol

LogP

1,90

TPSA

59,30 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O

InChI

InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)

Molecular Formula

C15H13NO3

HBD / HBA

1 / 3

Liaisons Rotatives

3

Atomes Lourds

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A potent NSAID used for short-term management of moderate to severe pain, including postoperative pain and pain associated with certain cancers. It is available in oral, injectable, and nasal spray forms and works by blocking prostaglandin synthesis.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Ketorolac is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL469. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3826. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.